A panel of health industry leaders, hosted by the Alliance for Health Reform, gathered together representatives from Hospira, Amgen, the FDA and other industry experts to discuss the future of biosimilars in the U.S.
Alliance executive vice president, Ed Howard, moderated the event, where expert panelists discussed the U.S. and global markets for reference biologics and biosimilars, outlined current policy and regulatory issues, and described implications for the future of the U.S. biosimilars industry.
Concerns over naming of biosimilars were also discussed, with some panellists suggesting that assigning a unique name to biosimilars will put them at a disadvantage to innovator products.
